Whetstone Capital Advisors LLC Purchases New Position in Health Catalyst, Inc. $HCAT

Whetstone Capital Advisors LLC purchased a new stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 1,705,072 shares of the company’s stock, valued at approximately $7,724,000. Health Catalyst accounts for approximately 3.4% of Whetstone Capital Advisors LLC’s holdings, making the stock its 10th biggest position.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Group One Trading LLC increased its position in shares of Health Catalyst by 107.6% during the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock valued at $31,000 after buying an additional 2,260 shares during the period. Aquatic Capital Management LLC purchased a new position in shares of Health Catalyst during the fourth quarter valued at about $63,000. XTX Topco Ltd purchased a new position in shares of Health Catalyst during the first quarter valued at about $54,000. Brevan Howard Capital Management LP purchased a new position in shares of Health Catalyst during the fourth quarter valued at about $92,000. Finally, Jump Financial LLC purchased a new position in shares of Health Catalyst during the fourth quarter valued at about $112,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Citigroup cut shares of Health Catalyst from a “buy” rating to a “neutral” rating and reduced their price target for the company from $6.50 to $3.50 in a research report on Friday, August 8th. Wells Fargo & Company cut their price objective on shares of Health Catalyst from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, August 11th. Evercore ISI cut their price objective on shares of Health Catalyst from $5.00 to $4.00 and set an “in-line” rating on the stock in a report on Wednesday, July 9th. Stifel Nicolaus cut their price objective on shares of Health Catalyst from $5.50 to $4.50 and set a “hold” rating on the stock in a report on Friday, August 8th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $4.00 price objective (down previously from $9.00) on shares of Health Catalyst in a report on Friday, August 8th. Five analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $6.18.

Health Catalyst Trading Down 2.7%

Shares of NASDAQ HCAT opened at $2.92 on Thursday. The firm’s 50 day moving average price is $3.68 and its 200-day moving average price is $4.12. The company has a market cap of $205.48 million, a PE ratio of -1.93 and a beta of 1.46. Health Catalyst, Inc. has a 52-week low of $2.52 and a 52-week high of $9.24. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.83 and a current ratio of 1.83.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.